Christophers E. Psoriasis—Epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314–20.

Article  CAS  PubMed  Google Scholar 

Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133:377–85.

Article  CAS  PubMed  Google Scholar 

Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. https://doi.org/10.3390/ijms20061475. PMID: 30909615; PMCID: PMC6471628.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263–71.

Article  CAS  PubMed  Google Scholar 

Boehncke WH, Sch€on MP. Psoriasis. Lancet. 2015;386:983–94.

Article  CAS  PubMed  Google Scholar 

Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20.

Article  PubMed  Google Scholar 

Branisteanu DE, Cojocaru C, Diaconu R, Porumb EA, Alexa AI, Nicolescu AC, et al. Update on the etiopathogenesis of psoriasis (Review). Exp Ther Med. 2022;23(3):201. https://doi.org/10.3892/etm.2022.11124. Epub 2022 Jan 5. PMID: 35126704; PMCID: PMC8794554. The review of this literature assesses the recent findings on the etiopathogenesis of psoriasis and their relationship with the genetic factor, AMPs, the IL23/Th17/IL17 axis, TRMs and Tregs.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mahil SK, Capon F, Barker JN. Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol. 2016;38:11–27.

Article  CAS  PubMed  Google Scholar 

Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets. 2008;12:1085–96.

Article  CAS  PubMed  Google Scholar 

Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004;135:1–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-αlpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci. 2005;102:19057–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol. 2005;175:2721–9.

Article  CAS  PubMed  Google Scholar 

Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176:1908–15.

Article  CAS  PubMed  Google Scholar 

Li HH, Lin YC, Chen PJ, Hsiao CH, Lee JY, et al. Interleukin-19 upregulates keratinocyte growth factor and is associated with psoriasis. Br J Dermatol. 2005;153(3):591–5.

Article  CAS  PubMed  Google Scholar 

Boniface K, Bernard FX, Garcia M, et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol. 2005;174:3695–702.

Article  CAS  PubMed  Google Scholar 

Riojas ME. Psoriasis treatment: a literature review. Int J Res Dermatol. 2023;9:314–7. This article is significant because it offers a thorough explanation of the disease's pathophysiology, which aids in the development of better and more innovative treatment options.

Article  Google Scholar 

Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44(12):1341–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mudter J, Yu J, Zufferey C, Brüstle A, Wirtz S, Weigmann B, et al. IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivo. Inflamm Bowel Dis. 2011;17(6):1343–58.

Article  PubMed  Google Scholar 

Brüstle A, Heink S, Huber M, Rosenplänter C, Stadelmann C, Yu P, et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol. 2007;8(9):958–66.

Article  PubMed  Google Scholar 

Vander Lugt B, Khan AA, Hackney JA, Agrawal S, Lesch J, Zhou M, et al. Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation. Nat Immunol. 2014;15(2):161–7.

Article  CAS  PubMed  Google Scholar 

Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, et al. IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity. 2013;38(5):970–83.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marrakchi S, Guigue P, Renshaw BR, Puel A, Pei X-Y, Fraitag S, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011;365(7):620–8.

Article  CAS  PubMed  Google Scholar 

Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301(10):555.

Article  CAS  PubMed  Google Scholar 

Bhutani T, Busse K, Koo J. Revisiting cyclosporine in the age of biologics: update on efficacy and mechanism of action. Prac Dermatol. 2010;28–32.

Cowden A, Van Voorhees AS. Introduction: History of psoriasis and psoriasis therapy. In: Weinberg JM, editor. Treatment of Psoriasis. Birkhäuser Basel: Milestones in Drug Therapy; 2008.

Google Scholar 

Borel J, Fuerer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976;6(4):468–75.

Article  CAS  PubMed  Google Scholar 

Chapman I, Mazzoni L. Mechanisms of inhibition by cyclosporin A on pulmonary leukocyte accumulation. Trends Pharmacol Sci. 1994;15:99–101.

Article  CAS  PubMed  Google Scholar 

Ryffel B, Willard-Gallo KE, Tammi K, Loken MR. Quantitative fluores- cence analysis of cyclosporine binding to human leukocytes. Trans- pla nta tion. 1984;37:276–80.

CAS  Google Scholar 

Ohtsuki M, Nakagawa H, Sugai J, et al. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis. J Dermatol. 2003;30:290–8.

Article  CAS  PubMed  Google Scholar 

Dos Reis G, Shevach EM. Effect of cyclosporin A on T-cell function in vitro: a mechanism of suppression of T cell proliferation depends on the nature of the T-cell stimulus as well as the differentiation state of the responding T-cell. J Immunol. 1982;129:2360–7.

Article  PubMed